BOOST-II long term outcomes

The long-running epic of the oxygen saturation targeting trials is nearing completion. This publication of the joint results of the Australia and UK trials now includes the primary outcome for the trials, the combined rate of death or “disability”. Australia Boost-II and United Kingdom Collaborative Group. Outcomes of Two Trials of Oxygen-Saturation Targets in Preterm Infants. The New England journal of medicine. 2016. Disability is defined as being a cognitive or language score on the Bayley-3 of less than 85, severe visual loss, or disabling CP (GNFCS of 2 or more). I will avoid (for a change) ranting about the inappropriateness of referring to a Bayley cognitive or language score of less than 85 as a “disability”.

Because of what happened during the trials the analysis can seem quite complex. But the overall message is that the adverse outcome was increased in the low saturation group when the two trials are combined, however you slice the data.

In case there are any readers who don’t know, a calibration artefact was discovered during the trials, which was corrected, leading to each of these trials, and the COT trial, to have babies with oximeters from a before-correction group and an after-correction group. In the two trials, the difference in mortality only occurred after the change in oximeter algorithm, whereas the smaller NZ trial used only the original algorithm and didn’t find an effect on mortality (or on long term outcome) and SUPPORT, with somewhat different entry criteria, did show a difference in mortality despite using only the original oximeters. The Canadian Oxygen Trial also showed a higher mortality in the low saturation group after the oximeter adjustment, but it didn’t reach statistical significance.

The new publication shows no effect of the trial on “disability”, but the analysis of the primary outcome “death or disability” was significant for the pooled data. What gets complicated is that the UK group changed their primary outcome during the trial to be the rate of death or disability with the revised oximeters, whereas the Australians kept this as the whole group. In the UK the oximeters were changed after roughly ¼ of the babes were enrolled, while in Australia 3/5 of the babies were studied with the original devices.

So the primary outcome analysis of the original trials presented doesn’t include some of the randomized babies (in the UK trial), which bothers me a bit, but their data are presented and analyzed. And then there is quite a lot of detail in one of the tables. The combined outcome of death or disability was significant for the pooled data which included all of the randomized babies (48% vs 43%) and not far from significant for the revised oximeters (49% vs 44%, RR 1.12, 95% CI 0.99-1.27). As I mentioned above, there isn’t any sign of an effect on disability, the difference is all in mortality, now updated to mortality before 2 years of age, most dramatically when the analysis is restricted to the revised oximeters. For the revised oximeters alone the relative risk of death in the low saturation target group was 1.45, (95% CI 1.16 to 1.82).

As everyone now who has Masimo oximeters, they use the new algorithm, and other oximeters were never affected, this is the part of the results which is now most relevant, and I think needs to be taken very seriously.

One comment I would like to make is that the primary analysis for the trials is described as “pre-specified”. But how can the analysis by oximeter algorithm be pre-specified if the problem was discovered during the trial? Pre-specified is supposed to mean, “determined before the trial started”. I think the analysis is just fine, the dilemma about what to do when this was discovered part way through a trial is not easily resolved, and the different choices of the 2 trials can both be justified. It is the use of the word “pre-specified” that I think is incorrect. Also the definition of disability was changed after the study commenced as they (quite appropriately) changed from the Bayley version 2 to the Bayley version 3. The authors describe these events quite clearly in the text, but as they were changed after the trial started they shouldn’t be referred to as pre-specified. the authors are using the term to mean specified before the analysis was started, which  is of course essential and very important, to avoid picking data that look interesting after they have been collected.

To end the saga that I mentioned at the beginning now only needs the NeoPROM collaborative to analyze the individual patient data. It’s hard to think that this will give any result other than an increase in mortality with the lower oxygen target.

One other outcome of interest is that in this trial, as in all the others, there was no increase in blindness. This despite an increase in retinopathy requiring treatment. This was also seen in the SUPPORT trial, but there was no increase in retinopathy in COT. I think this means we can be a bit re-assured that the use of carefully targeted saturations in the low 90’s will not lead to a new epidemic in blindness; but should not be sanguine about the risks of targeting the higher saturation group, treatment of retinopathy is not, by any means, without consequences, even if we can usually prevent blindness, very severe myopia, loss of peripheral vision, and poor cosmetic results are common.

Posted in Neonatal Research | Tagged , , , | 1 Comment

Antenatal Steroids at 36 weeks?

Most of the studies of antenatal steroids for lung maturation included mothers at less than 34 weeks. Most babies at 34 to 36 weeks do fine, although there is a growing realization of their increased long term risks. Even the proportion who develop respiratory disease usually have relatively short-lived disease, and rarely get very sick, although that can happen. Therefore, to show the efficacy and safety of steroids at later preterm gestational ages you would need to perform a very large study.

So here it is…

Gyamfi-Bannerman C, et al. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. The New England journal of medicine. 2016; 2800 mothers at risk for preterm delivery at 34 weeks 0 days up to 36 weeks and 5 days were randomized to IM betamethasone or IM placebo. Mothers were not eligible if they were expected to deliver in less than 24 hours, in order to try and get enough time for the steroids to have optimal effect. In fact the median time from starting the intervention until they did indeed deliver was about 30 hours, with interquartile range from 14 to 110 hours.

The primary outcome was a composite made up of signs of respiratory failure, including needing CPAP (or high flow cannulae) for more than 2 hours, or needing more than 30% oxygen for over 4 hours, or being ventilated. That outcome was decreased from 14.4% (placebo) to 11.6% (betamethasone). Among other secondary outcomes, there was also a reduction in the “need for resuscitation at birth” which was defined as : any intervention in the first 30 minutes other than blow-by oxygen, This dropped from 18.7% to 4.5%

Which all sounds great.

BUT.

The incidence of hypoglycemia (blood sugar under 2.2 mmol/L, that’s 40 mg/dl for the Americans) was greatly increased, from 15% to 24% in the steroid group. There were no other safety issues identified, maternal adverse effects were similar in the 2 groups, and there was no increase in infection (maternal or neonatal). I can’t tell from the data presented how many of the babies needed invasive treatment for their hypoglycemia, or how many had more severe hypoglycemia.

If that is a real effect of the antenatal steroids, I am not sure what the mechanism would be, I wouldn’t have thought that 30 hours of antenatal steroids would be enough to induce hyperinsulinism in the babies, but I do think this is a serious potential hazard of the steroids in this group. Almost all of the control babies recovered from their respiratory distress without a significant complication, so if the hypoglycemia had long-term consequences in some babies then the balance of benefits and adverse effects might not be positive.

For now this seems hopeful that antenatal betamethasone at 34 to 36 weeks could lead to an absolute risk reduction of 3% in the development of respiratory failure, a 0.7% decrease in the use of assisted ventilation. But unfortunately a 9% increase in hypoglycemia, most of which was presumably mild and of short duration. I am not sure that this should become routine therapy unless we can get some long term follow up. I for one hope the MFM units network of the NICHD will fund such a follow up to this study, at least to 3 years of age.

 

Posted in Neonatal Research | Tagged , | 1 Comment

Preventing and Treating Sepsis in Preterm Babies

These two studies are both issues that I am involved with, Theresa Ochoa’s study I was aware of, and was waiting for the full publication, the other, from Egypt, I didn’t know about but should have done, but it confirms the need for a large RCT.

Ochoa TJ, et al. Randomized Controlled Trial of Lactoferrin for Prevention of Sepsis in Peruvian Neonates Less than 2500 g. Pediatric Infectious Disease Journal. 2015;34(6):571-6.

This study enrolled just under 200 babies and randomized them to lactoferrin or placebo in three NICUs in Lima, Peru. It showed that routine lactoferrin prophylaxis reduced clinically diagnosed sepsis episodes in low birth weight infants, a reduction which was not quite significant on the primary statistical analysis, but if you are only interested in culture positive, “definite” sepsis, then there was no difference. The authors note that in low and middle income countries lab facilities may be limited, so a clear definition of clinical sepsis, might be the best that can be done. The study included babies up to 2.5 kg, and used a body weight adjusted dose of lactoferrin. In my pilot study (accepted for publication in the Journal of Perinatology), we also did not show a difference in sepsis, but our study was even smaller than this one (with 79 infants enrolled) so we knew we were underpowered for sepsis, but we did work out many of the mechanics of performing a masked RCT of lactoferrin.

Which means that we need other, larger, better powered studies. Hello ELFIN and LIFT, and hopefully soon LIFT-CAN!

Shabaan AE, et al. Pentoxifylline Therapy for Late-Onset Sepsis in Preterm Infants: A Randomized Controlled Trial. Pediatric Infectious Disease Journal. 2015;34(6):e143-e8. Pentoxifylline has many different actions, in particular it inhibits transcription of tumour necrosis factor-alpha, which might be a good thing in sepsis; also, according to the authors of this study, it

preserves microvascular blood flow, prevents circulatory failure and intestinal vasoconstriction and has beneficial effects on endothelial cell function and coagulation in sepsis.

This study randomized 120 newborn preterm babies with clinical signs of sepsis to get either pentoxifylline or placebo, starting with the first dose of antibiotics, and continuing for 6 days. The babies in the pentoxifylline group had inotropic support less frequently, and less intravascular coagulation and thrombocytopenia. There was a minor benefit in mortality with the treatment (10% vs 17%), and other differences between groups favoured the pentoxifylline babies.

The latest version of the Cochrane review of pentoxifylline notes that the data are currently inadequate to be sure that this is a good thing to do, but they are all, so far, positive. It concludes

Low-quality evidence from six small studies suggests that pentoxifylline therapy as an adjunct to antibiotics in neonatal sepsis decreases mortality without any adverse effects. We encourage researchers to undertake large, well-designed multicentre trials to confirm or refute the effectiveness of pentoxifylline in reducing mortality and morbidity in neonates with sepsis or NEC.

The NHMRC in Australia has just funded such a trial! I am privileged to be one of the investigators, for an international trial of 900 very preterm babies with sepsis or NEC who will get either pentoxifylline or placebo. Pentoxifylline is already licensed in many countries, for other indications, and is actually fairly cheap. So if this works in a well-performed trial then there is a real chance of doing good things for preterms around the world.

Posted in Neonatal Research | Tagged , | 1 Comment

Good Advice

Sometime you can find things on the Internet that are better than many medical help sites. Here is advice that can apply to almost anyone with a newborn baby who has a life-changing diagnosis, almost anytime.

Always remember this: “A diagnosis defines a lot of things, but it doesn’t define love”

Diagnosed

Posted in Neonatal Research | 1 Comment

Enhanced Nutrition

Strømmen K, et al. Enhanced Nutrient Supply to Very Low Birth Weight Infants is Associated with Improved White Matter Maturation and Head Growth. Neonatology. 2015;107(1):68-75. This is a report of a secondary outcome of a small RCT, there were only 50 babies in total (the study  was stopped early because of an increase in sepsis in the high nutrition group) and only 25 of them had the MR imaging; VLBW infants were randomized to standard nutrition, or an enhanced protocol which started IV amino acids at 3.5 g/kg/d increasing to 4.4.

Lipids were increased from 0.5 to 7 g/kg/day by day 10 in the control group and from 2.0 to 8.8 g/kg/day in the intervention group. The control group received the lipid emulsion ClinOleic ® (Baxter, Norway), whereas the intervention group received SMOFlipid ® (Fresenius Kabi, Norway) to ensure a higher supply of the essential fatty acids docosahexaenoic and arachidonic acid. The supply of proteins and lipids was gradually increased in both groups, mostly by increasing the enteral supply of human milk. Fortification was initiated when 110 ml/kg/day of human milk was tolerated with a gradual increase to 4.2 g Nutriprem /100 ml human milk. The intervention group received an additional enteral supply of amino acids (0.6 g Complete Amino Acid Mix)/100 ml human milk,

They also got additional docosahexaenoic acid and arachidonic acid.

Now I am all for enhanced nutrition, but that sounds really really enhanced, I don’t think I have ever given any where near that much lipid to a baby. The intervention group received a very high calorie intake, 166 kcal/kg/d, but even the controls got a lot of energy, 146 kcal. There was an even bigger difference in protein intake, 4.4 g/kg/d compared to 3.6 g. I have mentioned this study previously I think. it is a shame they stopped the study for a marginally significant finding on a secondary outcome, but I can certainly understand it, I don’t know if I would have had the guts, or the ruthlessly scientific approach, to continue a study when 61% of the intervention group have sepsis compared to 29% in the controls.

The point of this post though is that they did show that

1. Head circumference was closer to normal in the enhanced group

2. MRI Diffusion Tract Imaging (DTI) were much closer to normal in the enhanced nutrition group.

If the effect on sepsis is a real effect of the increased nutrition, then that outcome has to be balanced against the improved head growth and brain structure. Other studies, such as ours (which was not a randomized trial) did not show any increase in sepsis with increased nutrition, but we didn’t go near to their intakes. Is there a limit to calorie or fat or protein intakes that impairs white cell function? It certainly is possible, so we really need…. guess what? Randomized controlled trials, that’s what (suprise, surprise).

Posted in Neonatal Research | Tagged , , | Leave a comment

Neonatal Updates

Glasson EJ, et al. Improved Survival in Down Syndrome over the Last 60 Years and the Impact of Perinatal Factors in Recent Decades. The Journal of pediatrics. 2016;169:214-20.e1. This is a fascinating study, showing dramatic improvements in the survival of persons born with Down syndrome (trisomy 21) over the last 60 years with data from a linked western Australia database. Infants with Down syndrome are much more likely to be born preterm, and the survival disadvantage of having T21 is much greater for very premature babies with the diagnosis. Although the survival disadvantage of Down syndrome has diminished over the years, such that they know are 93% as likely to survive to 30 years of age as the general population, the same is not true of premature babies with T21, who still have a major survival disadvantage. Of course this kind of study can’t say why that is, are premature babies with T21 more fragile? Do they have more serious complications of prematurity? Or are attitudes still a problem, with less intensive care given to these babies, with a greater willingness to limit care?

Schwarz CE, et al. Repeatability of echocardiographic parameters to evaluate the hemodynamic relevance of patent ductus arteriosus in preterm infants: a prospective observational study. BMC Pediatrics. 2016;16(1):1-5. This also I found a little surprising, but maybe I shouldn’t have, measuring things with ultrasound in tiny preterm babies often approaches the limits of resolution of the technology. For example a study which tells you that the diameter of the PDA is 1.8 mm, if your cutoff for treatment is 1.6mm, should probably be repeated, by another person, who doesn’t know the results of the first study. The second study might give you such a different answer that you would change your treatment decision, and the same is true for all the indices of whether a PDA is significant or not.

Baxter B, et al. Neonatal lumbar puncture: are clinical landmarks accurate? Archives of Disease in Childhood – Fetal and Neonatal Edition. 2016. This study also makes me question what I do, the usual landmark for doing an LP, the line between the 2 iliac crests, is a very poor indicator of the lumbar segment, and a worryingly poor indicator of the end of the spinal cord. Makes me wonder if we should find another anatomic landmark, or whether we should routinely do a spinal ultrasound to find the right point.

Shetty S, et al. Work of breathing during CPAP and heated humidified high-flow nasal cannula. Archives of Disease in Childhood – Fetal and Neonatal Edition. 2016. High flow cannulae at 8 litres per minute, or 6 litres for babies less than 1 kg, were compared with CPAP at 6 cmH2O. There were no differences in calculated work of breathing, or in thoracic/abdominal asynchrony, or in saturations.

Posted in Neonatal Research | 1 Comment

Interesting comments

I get a small number of comments on the blog, almost always interesting, depending on how you view the content you may not have noticed them.

Three of my recent posts have stimulated some comments that are worthwhile: If you click on the links below, it should open an individual page with the comments at the bottom, and my replies if there are any.

Please feel free to leave comments on my posts, your first comment will have to be approved by me, in order to avoid spam. WordPress filters out a lot of spam (hundreds and hundreds of comments that come from weird people who have invented automated comment posts for blogs from places such as lasixwithoutprescription.com and onlinepokerfrommalaysia.net) but there are still a few that get through that I have to delete manually. I will approve any comment that is from a real person, relevant to the purposes of the blog, and is not abusive. Even if I disagree with you!

ventilating-infants-with-diaphragmatic-hernia

The death knell for Xenon?

How-frequent-is-acute-kidney-injury-in-the-NICU? Not-as-frequent-as-some-publications-would-have-you-believe

And here is one comment from a parent

A new publication

Posted in Neonatal Research | Leave a comment

Ventilating infants with Diaphragmatic Hernia

Snoek KG, et al. Conventional Mechanical Ventilation Versus High-frequency Oscillatory Ventilation for Congenital Diaphragmatic Hernia: A Randomized Clinical Trial (The VICI-trial). Ann Surg. 2015.

There a few few remarkable things about this study; the first is part of the preamble:

Since 2008, all CDH patients born in European countries represented in the CDH EURO consortium have been treated according to a standardized neonatal treatment protocol that was developed at a consensus meeting. After implementation of this protocol, mortality decreased from 33% to 12%. This decrease in mortality rate should be interpreted against of the year upon year variability in mortality rates. Nevertheless, standardization of care is an ideal backcloth to undertake multicenter randomized controlled trials (RCTs).

In this study full term babies with an antenatal diagnosis of CDH were randomized to start on either conventional ventilation (Initial settings were a positive inspiratory pressure (PIP) of 20 to 25 cmH2O and a positive end-expiratory pressure (PEEP) of 3 to 5 cmH2O, with a ventilator rate of 40 to 60/min) or high frequency ventilation (mean airway pressure 13 to 17 cmH2O, frequency 10 to 12 Hz, delta P 30 to 50 cmH2O depending on chest wall vibration). There were a fairly complex list of signs of failure of the initial ventilation mode (If these things happen for at least 3 hours: inability to maintain preductal saturations above 85% or postductal saturations above 70% ; increase in CO2 > 65 mm Hg despite optimization of ventilatory management; PIP > 28 cmH2O; mean airway pressure >17 cmH2O; inadequate oxygen delivery with metabolic acidosis defined as lactate 5 mmol/L and pH < 7.20; hypotension resistant to fluid therapy and inotropic support resulting in a urine output <0.5 ml/kg/hour; oxygenation index of 40). In which case they could be switched to the other ventilation mode, and if that didn’t work they could be placed on ECMO.

The primary outcome of the study was survival without chronic lung disease (oxygen requirement at 28 days). Over 5 years they enrolled 171 patients, far short of the hoped for 200 per group. In the Conventional group 45% died or had chronic lung disease compared to 53% in the HFO group, a difference which may have been due to chance, (p= 0.3). Many of the secondary outcomes were better in the conventional group, there was much less need for ECMO (26% vs 51%), they were ventilated for fewer days,
less often received inhaled nitric oxide, or sildenafil, had a shorter duration of
vasoactive drugs, and less often failed treatment.

I think the study is a remarkable achievement, as far as I can see this is by far the largest RCT of infants with CDH that has ever been performed. Even though it was unfortunately stopped before the full sample size, it looks unlikely that an advantage of initial HFO would have been shown. As we are unlikely to have any other data of this quality for a very long time, I think the conclusion should be that the starting assisted ventilation mode for infants with CDH should be conventional ventilation, unless there is some very good reason for choosing HFO.

We can only hope that this collaborative group will continue to perform important clinical studies in these babies, who remain a group with very high mortality despite the advances of the last several years. I would vote for a good trial of sildenafil, a comparison of different criteria for ECMO, and more studies of different aspects of assisted ventilation. Maybe a study of muscle relaxation as well, if that wasn’t asking too much!

Posted in Neonatal Research | 6 Comments

A New Publication

Janvier A, Farlow B, Barrington KJ. Cardiac surgery for children with trisomies 13 and 18: Where are we now? Seminars in Perinatology. 2016. Annie and Barb and I have just published this review of the current situation regarding cardiac surgery for infants with the aneuploidies in the title. (For those who don’t know, Barb Farlow is a mother of a child, who has sadly died, who had trisomy 13.) In addition to discussing the literature we make some recommendations about how to help families making difficult decisions. The literature review is limited by the common practice of lumping together all kinds of cardiac surgery, from ASD repairs to Fontan procedures and Norwoods. Also few papers describe whether there was withholding or withdrawal of life-sustaining interventions at any time.

Nevertheless, it is clear that prolonged survival after cardiac surgery is possible.

Our hope is that we will move away from the universal denial of cardiac surgery, which still occurs in some places. On the other hand it is not appropriate, for any patient, to ignore their other problems pretending they don’t exist, infants with aneuploidies often have other difficulties, which may be serious, but which are very variable. Only by making a decision with the parents which is medically appropriate, likely to improve their life, and consistent with the families values, will we be able to truly act in their best interests.

We offer some guidance which will hopefully be helpful, this is an abbreviated version of our suggestions.

(1) Words are important, avoid these words: “vegetable,” “futile,” “lethal,” “incompatible with life,” “waste of time/resources/emotions,” “Tee 13 or 18,” “it, that,” “product of conception,” “hopeless,” “nothing we can do.”

(2) Avoid unfounded and biased predictions: do not tell parents that this child will have a negative impact on their family, their other children, or their lives.

(3) Recognize that each child and family is unique

(4) Provide balanced counseling: which includes recent medical information, as well as the experience of families who live(d) with children with these conditions.

(5) Personalize the information: all infants are different, even if they carry the same label.

(6) One step at the time: decisions about potential complex cardiac interventions need not be discussed and decided upon prenatally, but be forthright about care options for stable children.

(7) Provide parents with different possible outcomes for their fetus/child (including stillbirth): emphasize the spectrum and uniqueness of each child and the lack of control you and they have on many of these outcomes.

(8) Empower parents: recognize that this diagnosis is difficult for parents, that they are doing their best.

(9) Offer reasonable hope:  hope that their child might defy the odds and hope that her life, however long, will have an enriching and positive influence on all who love her.

(10) Support parents: ask them how you can help them.

We hope that families facing these decisions will find caregivers who are sensitive to their needs, willing to consider the options, and supportive.

Posted in Neonatal Research | 2 Comments

The death knell for Xenon?

Azzopardi D, et al. Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial. The Lancet Neurology. 2016;15(2):145-53.  Babies who undergo therapeutic hypothermia for perinatal encephalopathy are still at high risk of significant long term impairments. Other therapies to add to hypothermia are being sought and tested, one of them being Xenon. Inhaled xenon gas has neuroprotective effects in many models; but it is expensive and difficult to use, in order to make it affordable for use over several hours you need to recirculate the exhaled xenon, so you need a special ventilator, which has been developed for this trial. In this “pilot’ RCT, eligible babies were typical of infants who are cooled, and had to have started on hypothermia within 6 hours after birth. As is usual, most of the 92 enrolled babies (2/3) were born in peripheral hospitals and transported in, many babies were cooled quite quickly, 93% before 4 hours of age. Xenon or standard care was started after randomization which was after arrival in the study centre, so the assigned treatment didn’t start until an average of 10 hours of age.  Xenon (or no xenon) was then continued for exactly 24 hours of age.

The primary outcomes of the study were MR findings; using spectroscopy they calculated the ration of lactate to N-acetyl aspartate in the thalamus, and using diffusion tensor imaging they calculated the fractional inosotropy of the posterior limb of the internal capsule. Scans were performed after the end of cooling at about 6 days of age. Because of deaths and a small number of scans not done in survivors, they ended up with around 75 babies with data for each of the two primary outcomes, data from the MRI were analyzed by a masked individual (images of the lone ranger… radiologist) . Basically the study showed no effect of Xenon.

Which is a bummer.

Why didn’t it work? I think first off we have to be careful in saying it didn’t work, there was no effect on the primary outcomes, but the primary outcomes are surrogates. Surrogates should always be mistrusted, even when they are called “biomarkers”. Is the surrogate an accurate enough predictor of good or adverse clinically important outcomes? I think that is questionable here, mostly because I don’t know the data well enough to answer the question, but is it possible that a clinically significant benefit of xenon will be shown if (hopefully when) these babies are followed up? My guess is that such an outcome is quite unlikely, but possible. In fact I think this study is a good opportunity to prove the value of the MR surrogates. If the authors are right (and usually Dennis Azzopardi, Dave Edwards and the many associated luminaries who wrote this article are indeed right) then using similar surrogates in future trials will help to screen for effective adjunctive therapies in cooled babies, and more quickly than waiting 2 years or so for follow up.

Maybe starting xenon at 10 hours of age is just too late? As the authors point out, they performed a trial in a real world environment, it would be possible, if you had the ventilator always ready and available, to start Xenon the moment a baby enters the referral NICU, but that would still lead to significant delays of evaluation and transport. Maybe 24 hours is too short? It was based on the best previously available literature, and again technically feasible, before doing another study with longer Xenon administration I think we would need some very good rationale.

In the end, this real-life application of xenon in cooled babies didn’t show any sign of being effective. We should look elsewhere I guess, something that could be given very quickly when a baby is cooled, such as melatonin, or erythropoietin look like they are the most worthy of further investigation. A review of the literature from 3 to 4 years ago concluded that, and I haven’t seen much to change the situation since then. Robertson NJ, et al. Which Neuroprotective Agents are Ready for Bench to Bedside Translation in the Newborn Infant? The Journal of pediatrics. 2012;160(4):544-52.e4.

Posted in Neonatal Research | Tagged , | 4 Comments